Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 50 of 53 · 2513 articles
This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...
Based on the title and source metadata, this appears to be a patient story related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from wellandgood.com.
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
Early-stage work on a new bispecific antibody could point to a different immune-regulatory approach for treating inflammatory bowel disease. Patients and clinicians watching IBD drug development may find the mechanism...
Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.
People with IBD — especially men — may have higher long-term risk of ischemic heart disease according to this large observational study. That could influence discussions about cardiovascular risk assessment and...
This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.
Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...
Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Gallstones, and Complications.
This signals new investigational IBD research focused on a novel immune pathway (TL1A/DR3) that could lead to future treatments. For people with Crohn’s/IBD, it’s an early-stage development to watch, but not an immediate...
Cure8 found this source from rollingout.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Symptoms and flares. Open the original article for the full details.
Local support groups can provide practical tips, emotional support, and community connections for people living with Crohn’s disease or ulcerative colitis. This meeting offers both in-person and virtual options, making...
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.
Bowel obstruction is a potentially serious complication of Crohn’s disease that may need urgent treatment. The article summarizes common causes (strictures, adhesions, tumors), typical symptoms to watch for, and the...
This article describes implantable vagus nerve stimulators being studied as a way to reduce inflammation in autoimmune diseases, including Crohn’s disease. If effective, these devices could offer a non-drug option or...
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Vedolizumab. The original article is from insights.citeline.com.
Surgical technique at the site of anastomosis can affect post-operative recurrence and recovery in Crohn’s disease. A simpler, faster stapled Kono-S might make this recurrence-reducing approach more accessible to...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from cureus.com.
Fundraising events like this support research and patient services for people with Crohn’s disease and ulcerative colitis. They also raise public awareness about IBD, which can reduce stigma and increase community...
Knowing the type of Crohn’s disease helps explain where symptoms come from and what treatments or procedures might be considered. The article links specific symptoms and complications to each anatomical pattern of...
New FDA approval adds another IL‑23p19 biologic option for moderate‑to‑severe Crohn’s disease and highlights two‑year efficacy data, which may affect treatment choices and future pediatric availability.
Cure8 could only read part of this source from morningstar.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Mirikizumab, and IL-23 inhibitor.
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Procedures and surgery. Open the original article for the full details.
A test that more accurately predicts which IBD patients with pre-cancerous bowel changes will develop cancer could help target surveillance and treatment to those at higher risk and reduce unnecessary procedures for...
Pregnancy planning and contraception are important for people with IBD because active disease at conception is linked to worse pregnancy outcomes. The article shows many women with IBD are unsure about how contraception...
Firsthand reports from people living with Crohn's highlight how painful flares can be and that symptoms may include vomiting, fainting during severe pain, and extraintestinal inflammation. This can help others recognize...
The study identifies a specific bacterial protein region (flagellin epitope) that many Crohn’s patients make antibodies to, which could help diagnose disease and predict who may develop complications.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease and Medications. The original article is from firstwordpharma.com.
Diet is a modifiable factor that may influence inflammation and the gut microbiome. If the Mediterranean diet is linked with lower disease activity and inflammatory markers in newly diagnosed Crohn’s disease, patients...
Based on the title and source metadata, this appears to be a patient story related to Crohn's disease and Community and awareness. The original article is from msn.com.
Cure8 could only read part of this source from healthcentral.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis.
Fundraising events support IBD research, programs and patient services. Money raised can contribute to work on personalized treatments and diagnostic tools that might benefit people with Crohn’s disease or ulcerative...
Public figures disclosing a Crohn's disease diagnosis can raise awareness and reduce stigma. People with Crohn's or IBD may relate to the challenges of balancing health, work, and family.
Cure8 found this source from telecomasia.net, but the page could not be read reliably yet. It is tagged for Crohn's disease and Community and awareness. Open the original article for the full details.
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from jewishpress.com.
Cure8 could only read part of this source from morningstar.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...
High-profile athletes speaking openly about Crohn’s disease raise public awareness and can help normalize conversations about living with IBD. Riiber’s description of symptoms, treatment effects, and impact on...
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....
Cure8 could only read part of this source from whatech.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.
Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Inflammatory bowel disease, and Biomarker. The original article is from firstwordpharma.com.
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...
This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...
Based on the title and source metadata, this appears to be a market or business news related to Inflammatory bowel disease, Crohn's disease, and Research and clinical trials. The original article is from...
A pipeline overview can indicate which new drugs and trials might affect future treatment options for Crohn’s disease. Patients on biologics or those with treatment-refractory disease may see new options under study that...
The event raised funds for the Crohn’s & Colitis Foundation, which supports IBD research, education, and patient care. Community fundraising events can expand local support networks and resources for people living with...
This article reassures people with Crohn’s that newer medications can control inflammation and lower complication and surgery risk. It also highlights the kinds of complications to watch for and ongoing research into...
